#USA #New York #Securities Fraud #Levi Korsinsky #MoonLake Immunotherapeutics

Investors Alert: Your Rights with MoonLake Immunotherapeutics

Levi & Korsinsky, LLP, a renowned law firm specializing in securities litigation, has issued an urgent notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX). Investors must act before December 15, 2025 if they wish to protect their rights in light of a class action lawsuit aimed at seeking compensation for losses attributed to alleged securities fraud.

Understanding the Class Action

The class action targets investors adversely affected between March 10, 2024 and September 29, 2025. The lawsuit raises fundamental concerns about misleading statements made by the company regarding its drug candidate, SLK, and its claimed advantages over existing therapies, particularly BIMZELX. The complaint specifically alleges that the defendants:

• - Failed to disclose that both SLK and BIMZELX target the same inflammatory cytokines, IL-17A and IL-17F.
• - Made false assurances that SLK’s unique Nanobody structure would result in better clinical outcomes.
• - Claimed that SLK’s Nanobody structure would lead to superior tissue penetration and efficacy, despite lacking a solid foundation for these assertions.

This situation has left many investors questioning the validity of their investments, prompting the need for legal recourse.

Participants in the Class Action

Investors who believe they suffered losses during the designated timeline are encouraged to contact Levi & Korsinsky. As a member of this class, you have the right to request the appointment as the lead plaintiff. It is important to note that you may still be eligible for compensation even if you do not take on the lead role, removing any burdens regarding legal fees; class members can potentially benefit from this action at no direct cost.

Contacting Levi & Korsinsky
Joseph E. Levi, Esq., and Ed Korsinsky, Esq. are leading this effort and can be reached for consultations via email at email protected] or through telephone at (212) 363-7500. For further details and to fill out a submission form for class action participation, visit their [dedicated link.

Why Choose Levi & Korsinsky?

Levi & Korsinsky boasts a remarkable track record, having secured hundreds of millions of dollars for distressed shareholders over two decades. The firm collaborates with a dedicated team of over 70 professionals who bring vast knowledge and experience to complex securities litigation. Their consistent performance has earned them a place on ISS Securities Class Action Services' Top 50 Report for seven consecutive years, solidifying their reputation as a leading firm in the industry.

Next Steps for Investors

If you have suffered losses related to your investment in MoonLake, timely action is crucial. Keep in mind that requests for lead plaintiff status must be completed by December 15, 2025. Engage with Levi & Korsinsky to understand your rights and explore your options for potential recovery.

Conclusion

The landscape of investment can often be fraught with uncertainty, especially when concerns of fraud arise. The ongoing case against MoonLake Immunotherapeutics presents a significant opportunity for harmed investors to address grievances and secure appropriate reparations. For more information on how to proceed, reach out to the legal experts at Levi & Korsinsky today. Protect your investment rights—take the first step toward recovery now.